Protocol Summary

Protocol No.: OCR13966

Sponsor Protocol No.: BEATAML

Study Title
Beat AML: Personalized Medicine for Acute Myeloid Leukemia Based on Functional Genomics

Principal Investigator(s)
Cogle, Christopher

In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential therapeutics for patients with acute myeloid leukemia (AML).

Phase: NA

Age Group: Adult

Scope: Local

Detailed Eligibility
1. Individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
2. Age between 18 and 80 years of age

Applicable Disease Sites

Participating Institutions
UF Gainesville

More Information:
View study listing on